STOCK TITAN
  1. Home
  2. Sec-filings
  3. ACAD
  4. [Form 4] ACADIA PHARMACEUTICALS INC Insider Trading Activity

Equity grants for ACADIA (ACAD) principal accounting officer

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
4

Rhea-AI Filing Summary

ACADIA PHARMACEUTICALS INC reported equity awards to its Principal Accounting Officer, James Kihara. He received a stock option for 21,766 shares of common stock at an exercise price of $22.16 per share and 6,332 restricted stock units, both as compensation-related grants.

According to the terms, 25% of the option vests and becomes exercisable on March 6, 2027, with the remaining shares vesting in 36 equal monthly installments after that date. The restricted stock units vest in four equal annual installments beginning March 6, 2027, each unit representing the right to receive one share of common stock. These are routine compensation awards, not open‑market purchases or sales.

Positive

  • None.

Negative

  • None.
Insider Kihara James
Role PRINCIPAL ACCOUNTING OFFICER
Type Security Shares Price Value
Grant/Award Stock Option (Right to Buy) 21,766 $0.00 --
Grant/Award Restricted Stock Units 6,332 $0.00 --
Holdings After Transaction: Stock Option (Right to Buy) — 21,766 shares (Direct); Restricted Stock Units — 6,332 shares (Direct)
Footnotes (1)
  1. 25% of the shares subject to the Stock Option will vest and become exercisable on March 6, 2027. The remaining shares vest and become exercisable in 36 equal monthly installments thereafter. Each restricted stock unit represents a contingent right to receive one share of Issuer's common stock. The restricted stock units vest in four equal annual installments beginning March 6, 2027.
See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
Form 4 Insider Transactions: What Each Field Means →
SEC Form 4
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response: 0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Kihara James
(Last) (First) (Middle)
C/O ACADIA PHARMACEUTICALS INC.
12830 EL CAMINO REAL, SUITE 400
(Street)
SAN DIEGO CA 92130
(City) (State) (Zip)
2. Issuer Name and Ticker or Trading Symbol
ACADIA PHARMACEUTICALS INC [ ACAD ] 		5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
Director 10% Owner
X Officer (give title below) Other (specify below)
PRINCIPAL ACCOUNTING OFFICER
3. Date of Earliest Transaction (Month/Day/Year)
03/06/2026
4. If Amendment, Date of Original Filed (Month/Day/Year)
 6. Individual or Joint/Group Filing (Check Applicable Line)
X Form filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Stock Option (Right to Buy) $22.16 03/06/2026 A 21,766 (1) 03/05/2036 Common Stock 21,766 $0 21,766 D
Restricted Stock Units (2) 03/06/2026 A 6,332 (3) (3) Common Stock 6,332 $0 6,332 D
Explanation of Responses:
1. 25% of the shares subject to the Stock Option will vest and become exercisable on March 6, 2027. The remaining shares vest and become exercisable in 36 equal monthly installments thereafter.
2. Each restricted stock unit represents a contingent right to receive one share of Issuer's common stock.
3. The restricted stock units vest in four equal annual installments beginning March 6, 2027.
/s/ Jennifer J. Rhodes, Attorney-in-Fact 03/10/2026
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

Source: View Original Filing on SEC EDGAR

FAQ

What equity awards did ACAD (ACADIA PHARMACEUTICALS) grant to James Kihara?

ACADIA granted James Kihara a stock option for 21,766 shares at a $22.16 exercise price and 6,332 restricted stock units. Both awards are compensation-related and settle in common stock, increasing his potential future ownership if vesting conditions are met.

How do the new stock options for ACAD’s Principal Accounting Officer vest?

The stock option vests 25% on March 6, 2027, with the remaining shares vesting in 36 equal monthly installments after that date. This creates a four-year vesting schedule designed to retain the executive over a multi‑year period.

What are the terms of the restricted stock units granted by ACAD to James Kihara?

The grant includes 6,332 restricted stock units, each representing a right to receive one share of common stock. These RSUs vest in four equal annual installments starting March 6, 2027, aligning long-term compensation with multi‑year company performance.

Did the ACAD insider Form 4 show any open‑market buying or selling?

No open‑market buys or sells are reported. The Form 4 only shows compensation grants: a stock option and restricted stock units awarded at no cash price, with future vesting schedules and no immediate market transactions involved.

What does the $22.16 exercise price on ACADIA’s stock option grant mean?

The $22.16 exercise price is the fixed price at which Kihara can buy ACADIA common shares under the option once portions vest. If the market price exceeds $22.16 after vesting, exercising could create value, aligning his incentives with share price performance.